Webinar

BEPO, the enabling technology to long-acting injectable adoption

Published

Format: External webinar | Document type: Webinar

BEPO, the enabling technology to long-acting injectable adoption
Already in clinical stage, BEPO is MedinCell proprietary long-acting injectable (LAI) platform based on a combination of copolymers, solvent and active pharmaceutical ingredient (API). BEPO provides controlled release of API for days, weeks or months from a fully bioresorbable depot that forms after subcutaneous or local administration. As a game-changing technology, BEPO combines the advantages of alternative drug delivery technologies, including improved patient compliance, efficacy and tolerability but also non-invasive administration, versatility, speed of development and low manufacturing costs.

Speakers

Adolfo Lopez Noriega Adolfo Lopez Noriega R&D group leader
MedinCell

Louise Lagerqvist Louise Lagerqvist Business Development Coordinator Coordinator
MedinCell

Stephane Lucchini Stephane Lucchini Business Director and Strategic Accounts Manager
MedinCell

Supplier info centre